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COPDAbstract Background: COPD is a widely distributed disease with high morbidity and mortality,
associated with different pathologies. The link between osteopontin, smoking and COPD needs
to be clariﬁed.
Objectives: To study the osteopontin serum levels in smoker COPD patients and ex-smoker
COPD patients.
Methods: Serum levels of osteopontin were measured in 38 male COPD patients divided into
smoker and ex-smoker groups using human osteopontin ELISA kits.
Results: There was a signiﬁcant difference between smokers and ex-smokers regarding their
serum osteopontin levels. There was no signiﬁcant difference in serum osteopontin level between
COPD patients regarding severity in both groups. There was a signiﬁcant difference in serum oste-
opontin level between the smokers group regarding their pack year index of smoking. There was no
signiﬁcant difference in serum osteopontin level between ex-smokers group regarding the duration
of cessation.
Conclusion: Serum level of osteopontin is increased in COPD patients and decreases with
cessation of smoking. It has no relation to disease severity.
ª 2014 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier
B.V. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is a
preventable and treatable disease with some signiﬁcant extrapulmonary effects that may contribute to the severity in indi-
vidual patients. Its pulmonary component is characterized by
airﬂow limitation that is not fully reversible. The airﬂow limi-
tation is usually progressive and associated with an abnormal
inﬂammatory response of the lung to noxious particles or gases
[1].
Cigarette smoking is the major risk factor associated with
the development of COPD; Heavy smokers are at greater risk
of developing COPD than moderate smokers [2].d.
64 A.A Ali et al.Osteopontin is a secreted phosphorylated glycoprotein
expressed in mineralized tissues and damaged renal tissues; it
is also expressed by immune cells during inﬂammation and
enhances the proinﬂammatory T-helper 1 cell response and
inhibits the T-helper 2 cell response [3].
Aim of the work
The aim of the current study was to study the osteopontin
serum levels in smoker COPD patients and ex-smoker COPD
patients.
Patients and methods
This work was carried out on 38 male patients with COPD
diagnosed and classiﬁed according to GOLD 2010 [1], referred
to chest hospital in Shebin El-Kom. The study also included
ten healthy male controls; their ages were matched with the
patients.
Subjects were divided into:
Group A: included 19 smoker patients with COPD and
were subdivided into: 14 patients with moderate COPD
and 5 patients with severe COPD.
Group B: included 19 ex-smoker patients with COPD and
were subdivided into: 12 patients with moderate COPD
and 7 patients with severe COPD.
Group C: included 10 healthy volunteers who had no symp-
toms or signs of any chest disease and had normal ventila-
tory function tests as a control group.
After having a written consent; each patient underwent:
1. Full history taking and clinical examination.
2. Chest X-ray.
3. Pulmonary function tests.
Morning spirometry was done and all patients had FEV1/
FVC of less than 70% and post bronchodilator spirometry
was performed after giving the patient a bronchodilator, such
as an inhaled beta-agonist e.g. salbutamol 400 lg) [4].
The following parameters were measured:
(a) Forced expiratory volume in the ﬁrst second (FEV1) pre
and post bronchodilator.
(b) Forced vital capacity (FVC).
(c) FEV1/FVC ratio.
(d) Peak expiratory ﬂow rate (PEFR).
Patients were classiﬁed according to GOLD staging system
(GOLD 2010) [1] into:
Stage I: mild COPD (FEV1/FVC < 70%; post bronchodi-
lator FEV1P 80% predicted).
Stage II: moderate COPD (FEV1/FVC < 70%,
50% 6 post bronchodilator FEV1 6 80% predicted).
Stage III: severe COPD (FEV1/FVC < 70%, 30% 6 post
bronchodilator FEV1 6 50% predicted).
Stage IV: very Severe COPD (FEV1/FVC < 70%, post
bronchodilator FEV1 6 30% predicted or postbronchodilator FEV1 6 50% predicted plus chronic respi-
ratory failure).
Serum osteopontin level was measured for all subjects using
human osteopontin ELISA kit.
Results
Table 1 shows the distribution of the studied groups regarding
GOLD stages of patients in each group (classiﬁed according to
GOLD 2010), and there was:
From 19 smoker patients in group (A), 14 (73.7%) had
moderate COPD, 5 (26.3%) had severe COPD. While from
19 ex-smoker patients in group (B), 12 (63.2%) had moderate
COPD, 7 (36.8%) had severe COPD. There was a non signif-
icant difference between smokers and ex-smokers groups as
regards the GOLD stage (P-value > 0.05).
Table 2 shows that the mean age of patients in group A was
55.89 ± 8.17 years. In group B; the mean age of patients was
54.73 ± 6.37 years. Lastly, in the control group (C); the mean
age of patients was 53.40 ± 9.45 years. There were insigniﬁ-
cant differences between the patients of both groups and
between them and the control group as regards age (P-
value > 0.05).
Table 3 shows a signiﬁcant difference between group (A)
and group (B) regarding their serum osteopontin level (P-
value < 0.01). There was also a signiﬁcant difference between
group (A) and the control group (C) (P-value < 0.01). How-
ever, there was a non signiﬁcant difference between group
(B) and group (C) regarding their serum osteopontin level
(P-value > 0.05).
Table 4 shows that there was no signiﬁcant difference
between moderate and severe COPD smokers as regards serum
osteopontin level (P-value 0.853).
Table 5 shows the non signiﬁcant difference between
moderate and severe COPD ex-smokers as regards serum
osteopontin level (P-value 0.673).
Table 6 shows that there was no signiﬁcant difference in
mean serum osteopontin level between ex-smokers group
regarding their duration of cessation (P-value 0.514).
Discussion
COPD is an inﬂammatory disease caused mainly by smoking
[5]. Osteopontin as a mediator of inﬂammation may be impli-
cated in the pathogenesis of a variety of disease states includ-
ing COPD and its complications [6].
This work was carried out on 38 patients with stable COPD
diagnosed clinically and by spirometry and classiﬁed into two
groups: Smokers (Group A) and Ex-smokers (Group B). In
addition to 10 healthy non smoker subjects as a control group
were included. Serum OPN was measured for all subjects.
In the present study, the results showed a signiﬁcant differ-
ence (P< 0.01) between smokers and ex-smokers regarding
their serum OPN level (higher in smokers), there was also a
signiﬁcant difference between group A and the control group
(P-value < 0.01). There was a non signiﬁcant difference
between group B and the control group regarding their serum
osteopontin level (Table 3). These results were matched with
the results of the studies carried out by Bishop et al. [7] who
Table 1 Distribution of the studied groups according to their GOLD stage.
Groups v2 P value
Smokers (A)
(n = 19)
Ex-smokers (B)
(n = 19)
No % No %
GOLD stage
Moderate (n= 26) 14 73.7 12 63.2 0.48 0.485 (NS)
Severe (n= 12) 5 26.3 7 36.8
Table 2 Distribution of the studied groups according to their age.
Groups F test Post hoc
Smokers (Group A)
(n= 19)
Ex-smokers (Group B)
(n= 19)
Controls (Group C)
(n= 10)
Mean ± SD Mean ± SD Mean ± SD
Age (years) 55.89 ± 8.17 54.73 ± 6.37 53.40 ± 9.45 0.34
P= 0.711
>0.05
(For all groups)
Table 3 Distribution of the studied groups according to their osteopontin level (pg/ml).
Groups Kruskal–Wallis test Post hoc value
Smokers (Group A)
(n= 19)
Ex-smokers (Group B)
(n= 19)
Controls (Group C)
(n= 10)
Mean ± SD Mean ± SD Mean ± SD
Serum osteopontin (pg/ml) A versus B (<0.01)
Mean 5453.40 1695.57 1687.65 19.71 A versus C (<0.01)
±SD ±3508.54 ±587.59 ±1423.88 <0.001 (HS) B versus C (>0.05)
Table 4 Comparison of serum osteopontin levels (pg/ml) in different GOLD stages in group (A).
Smokers GOLD stage Mann–Whitney P value
Moderate Severe
Mean ± SD Mean ± SD
Serum osteopontin (pg/ml) 5856.0 ± 3625.61 4326.20 ± 3243.09 0.18 0.853 (NS)
Table 5 Comparison of serum Osteopontin levels (pg/ml) in different GOLD stages in group (B).
Ex-smokers GOLD stage Mann–Whitney P value
Moderate Severe
Mean ± SD Mean ± SD
Serum osteopontin (pg/ml) 1718.0 ± 654.28 1657.20 ± 498.26 0.42 0.673 (NS)
Table 6 Comparison of serum osteopontin level (pg/ml) in ex-smokers according to the duration of cessation of smoking.
Ex-smokers Duration of cessation (Y) Mann–Whitney P value
<3 P3
Mean ± SD Mean ± SD
Serum osteopontin (pg/ml) 1802.20 ± 752.73 1577.10 ± 330.75 0.65 0.514 (NS)
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dent increase in osteopontin levels in cultured human endothe-
lial cells and this effect was signiﬁcantly reduced in the
presence of antioxidants, suggesting a role for oxidants in
the expression of osteopontin. Serum osteopontin levels were
lowered in human subjects whose oxidative stress/inﬂamma-
tory burden had likely been lowered by smoking cessation
[7]. Hillas et al. [8] found that osteopontin levels were signiﬁ-
cantly higher in COPD smokers compared to non-smokers,
and both non-smoking and smoking controls.
Berania et al. [9] showed that total white blood cell count
(as a marker of inﬂammation) was signiﬁcantly higher in active
smokers than in those who had never smoked and ex-smokers.
There was no signiﬁcant difference between moderate and
severe COPD smokers as regards serum osteopontin level
(Table 4). Also there was no signiﬁcant difference between
moderate and severe COPD ex-smokers as regards serum oste-
opontin level (Table 5). These results were in concordance with
the results of the study carried out by Zhao et al. [10] in which
there was no signiﬁcant association between OPN concentra-
tion and disease severity.
Ma et al. [11] studied serum osteopontin levels in patients
with stable chronic obstructive pulmonary disease and exacer-
bations. Osteopontin was higher in patients with acute exacer-
bation than with stable COPD and in healthy control subjects.
Lee et al [12] studied plasma osteopontin levels in COPD
patients classiﬁed into stable, frequent exacerbators and infre-
quent exacerbators, the results showed that patients with
COPD exacerbations had increased plasma OPN levels com-
pared with those with stable COPD and healthy controls, Also
frequent exacerbators had higher plasma osteopontin levels
compared with infrequent exacerbators. Accordingly, the pres-
ence of exacerbation and frequency of exacerbations are
important factors in elevating serum osteopontin levels in
patients with chronic obstructive pulmonary disease not the
stage of the disease.
In the current study, there was no signiﬁcant difference in
mean serum osteopontin level between ex-smokers group
regarding their duration of cessation; OPN levels were com-
pared in ex-smokers who quit smoking for less than three years
with ex-smokers who quit smoking for three years or more and
found no signiﬁcant difference between both groups (table VI).
These results can be explained by the results of Bishop et al. [7]
study which showed that in smokers who quit smoking for
5 days, serum osteopontin levels were signiﬁcantly lowered
compared to those measured prior to smoking cessation.
Accordingly we can predict that after less than six months of
smoking cessation, serum osteopontin level reaches a steady
level which will not be affected by longer duration of smoking
cessation.
Conclusion
From the present study we concluded that the serum level of
osteopontin is increased in smoker COPD patients. Osteopon-tin can be used as a new marker of inﬂammation caused by
smoking in COPD patients. OPN levels in COPD patients
have no relation to GOLD stage and it decreases with cessa-
tion of smoking.
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